- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02034162
A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants
September 16, 2016 updated by: Janssen Research & Development, LLC
A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment of Soil-Transmitted Helminth Infections (Ascaris Lumbricoides and Trichuris Trichiura) in Pediatric Subjects
The purpose of this study is to evaluate the efficacy and safety of mebendazole compared with placebo in pediatric participants with Helminth infections.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This will be a double-blind (neither physician nor participant knows the treatment that the participant receives), randomized (the study drug is assigned by chance), multi-center, parallel-group study (each group of participants will be treated at the same time) to evaluate the efficacy and safety of mebendazole (a drug currently being investigated for Helminth gastrointestinal infections) compared with placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial) in children (including pre-school and school-aged children) with Helminth infections.
The study will consist of 3 phases: a screening phase, a double-blind treatment phase, and a post-treatment (or follow-up) phase.
A pharmacokinetic (explores what a drug does to the body) open-label substudy (asks a separate research question from the parent study while using the same participant population but does not contribute to the parent study's objectives) will be included in the parent study to measure the level of mebendazole in the blood.
Safety assessments will be performed throughout the study.
Each participant will take part in the study for approximately 30 days.
Study Type
Interventional
Enrollment (Actual)
295
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 16 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Female participants who are >=9 years old must have a negative urine pregnancy test at screening or at the time of randomization
- Participants must be an otherwise healthy child, based on medical history, physical examination, vital signs, hemoglobin, and concomitant medications
- Participants >=3 years of age must have teeth and be able to chew
- Participant must be available to return to the study site for all visits, including the follow-up visit
- Parent(s)/guardians of participants (or their legally-accepted representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to have their child participate in the study
- Children 6 years of age and older will be asked to assent (agree) to their participation using appropriate language to their level of understanding; assent will be documented
Exclusion Criteria:
- Participant has active diarrhea (defined as the passage of 3 or more loose or liquid stools per day) at screening or at the time of randomization
- Participant has a significant medical disorder, participant has difficulty in chewing or swallowing
- Participant has significant anemia (<8 g/dL)
- Participant has significant wasting (greater than 2 standard deviations below the mean World Health Organization [WHO] Child Growth Standards for weight-for-height or body mass index)
- Participant has a known hypersensitivity to mebendazole, any inert ingredients in the chewable formulation
- Participant has preplanned surgery/procedures that would interfere with the conduct of the study during the course of study
- Participants has received an investigational drug (including vaccines) or used an investigational medical device within 30 days before the planned start of treatment, or is currently enrolled in an investigational study
- Employees of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator
- Participant has taken any form of medication containing mebendazole or any other treatment for soil transmitted helminth infection within 30 days of entry into the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Mebendazole
Mebendazole will be administered as a single 500-mg chewable tablet in a double-blind manner at the baseline visit (Day 1) and in an open-label manner at Visit 4 (Day 21).
|
Mebendazole will be administered as a single-dose 500 mg chewable tablet.
For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon.
The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles.
This semi-solid form can then be easily ingested by the child.
|
Placebo Comparator: Placebo
Matching placebo will be administered as a single-dose chewable tablet in a double-blind manner at the baseline visit (Day 1).
|
Matching placebo will be administered as a single-dose chewable tablet.
For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon.
The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles.
This semi-solid form can then be easily ingested by the child.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cure Rate for Ascaris Lumbricoides at the End of Double-blind Treatment Period
Time Frame: At Visit 3 (Day 19) of Double-blind treatment period
|
Cure is defined as a post-treatment egg count of zero in participants who had a positive egg count at baseline.
|
At Visit 3 (Day 19) of Double-blind treatment period
|
Cure Rate for Trichuris Trichiura at the End of Double-blind Treatment Period
Time Frame: At Visit 3 (Day 19) of Double-blind treatment period
|
Cure is defined as a post-treatment egg count of zero in participants who had a positive egg count at baseline.
|
At Visit 3 (Day 19) of Double-blind treatment period
|
Number of Participants Reporting Treatment Emergent Adverse Event (TEAE) in Double-Blind Treatment Period
Time Frame: Up to Visit 3 (Day 19 +/-2)
|
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Up to Visit 3 (Day 19 +/-2)
|
Number of Participants Reporting Treatment Emergent Adverse Event (TEAE) in Open-Label Treatment Period
Time Frame: At Visit 3 (Day 19+/-2) followed up to Visit 5 (Day 7+/-1 from Visit 3)
|
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
At Visit 3 (Day 19+/-2) followed up to Visit 5 (Day 7+/-1 from Visit 3)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Egg Count Reduction Rate (Percent) for Ascaris Lumbricoides Infestation at the End of Double-blind Treatment Period
Time Frame: Baseline and Day 19 (Visit 3) at the End of Double-blind Treatment Period
|
Percent egg count reduction is calculated as average egg count at end of treatment period of a treatment group minus average egg count at baseline of the treatment group divided by average egg count at baseline of the treatment group.
|
Baseline and Day 19 (Visit 3) at the End of Double-blind Treatment Period
|
Egg Count Reduction Rate (Percent) for Trichuris Trichiura Infestation at the End of Double-blind Treatment Period
Time Frame: Baseline and Day 19 (Visit 3) at the End of Double-blind Treatment Period
|
Percent egg count reduction is calculated as average egg count at end of treatment period of a treatment group minus average egg count at baseline of the treatment group divided by average egg count at baseline of the treatment group.
|
Baseline and Day 19 (Visit 3) at the End of Double-blind Treatment Period
|
Maximum Plasma Concentration (Cmax) of Mebendazole
Time Frame: Predose, 1, 2, 3, 5, 8 and 24 hours postdose at visit 4 (Day 20; 1 day after Visit 3)
|
The Cmax is the maximum plasma concentration.
|
Predose, 1, 2, 3, 5, 8 and 24 hours postdose at visit 4 (Day 20; 1 day after Visit 3)
|
Time to Reach Maximum Plasma Concentration (Tmax) of Mebendazole
Time Frame: Predose, 1, 2, 3, 5, 8 and 24 hours postdose at visit 4 (Day 20; 1 day after Visit 3)
|
The Time to Reach Maximum Plasma Concentration (Tmax) is time to reach the maximum plasma concentration.
|
Predose, 1, 2, 3, 5, 8 and 24 hours postdose at visit 4 (Day 20; 1 day after Visit 3)
|
Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours (AUC8h) of Mebendazole
Time Frame: Predose, 1, 2, 3, 5, 8 and 24 hours postdose at visit 4 (Day 20; 1 day after Visit 3)
|
The (AUC8h) is the area under the plasma concentration-time curve from time 0 to 8 hours Post-dose.
|
Predose, 1, 2, 3, 5, 8 and 24 hours postdose at visit 4 (Day 20; 1 day after Visit 3)
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-last) of Mebendazole
Time Frame: Predose, 1, 2, 3, 5, 8 and 24 hours postdose at visit 4 (Day 20; 1 day after Visit 3)
|
The (AUC [0-last]) is the area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration.
|
Predose, 1, 2, 3, 5, 8 and 24 hours postdose at visit 4 (Day 20; 1 day after Visit 3)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2014
Primary Completion (Actual)
September 1, 2015
Study Completion (Actual)
September 1, 2015
Study Registration Dates
First Submitted
January 9, 2014
First Submitted That Met QC Criteria
January 9, 2014
First Posted (Estimate)
January 13, 2014
Study Record Updates
Last Update Posted (Estimate)
November 4, 2016
Last Update Submitted That Met QC Criteria
September 16, 2016
Last Verified
September 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Parasitic Diseases
- Infections
- Communicable Diseases
- Helminthiasis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiparasitic Agents
- Antinematodal Agents
- Anthelmintics
- Mebendazole
- Piperazine
- Piperazine citrate
- DMP 777
Other Study ID Numbers
- CR100933
- MEBENDAZOLGAI3003 (Other Identifier: Janssen Research & Development, LLC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Helminth Infections
-
University of California, San FranciscoWithdrawn
-
University GhentCompletedSoil-transmitted Helminth InfectionsBangladesh, Cambodia, Ghana, Haiti, Lao People's Democratic Republic, Rwanda, Senegal, Vietnam
-
University GhentSwiss Tropical & Public Health InstituteCompletedSoil-transmitted Helminth InfectionsEthiopia, Lao People's Democratic Republic, Brazil, Tanzania
-
DBL -Institute for Health Research and DevelopmentUniversity of Zambia; Department of Community Medicine & Department of Biological...CompletedGrowth | Soil-Transmitted Helminth InfectionZambia
-
National Institute of Allergy and Infectious Diseases...CompletedFilarial Infection | Intestinal Helminth InfectionIndia
-
Noguchi Memorial Institute for Medical ResearchGhana Health ServicesCompleted
-
Boston Medical CenterRutgers, The State University of New Jersey; Jawaharlal Institute of Postgraduate...Active, not recruitingMalnutrition | Tuberculosis | Helminth InfectionIndia
-
London School of Hygiene and Tropical MedicineEmory University; University of California, Davis; Bill and Melinda Gates Foundation and other collaboratorsCompletedNutritional Status | Diarrhoea | Soil-transmitted Helminth InfectionIndia
-
Centre de Recherche Médicale de LambarénéCompletedDrug Resistance | Helminths InfectionGabon
-
London School of Hygiene and Tropical MedicineEmory University; Bill and Melinda Gates Foundation; KIIT University, Bhubaneswar... and other collaboratorsUnknownDiarrhea | Stunting | Soil-transmitted Helminth Infection | Enteric InfectionUnited Kingdom
Clinical Trials on Mebendazole
-
University of KelaniyaCompletedNecator Americanus InfectionSri Lanka
-
Janssen Research & Development, LLCCompleted
-
Johns Hopkins Bloomberg School of Public HealthAga Khan UniversityCompleted
-
DBL -Institute for Health Research and DevelopmentCompleted
-
Cornell UniversityJohns Hopkins Bloomberg School of Public Health; Bill and Melinda Gates Foundation and other collaboratorsActive, not recruitingAnemia | Low Birth Weight | Neonatal MortalityTanzania
-
University GhentVLIR-UOS Institutional University CooperationCompletedInfection by Trichuris TrichiuraEthiopia
-
RDD Pharma LtdWithdrawn
-
Annick DesjardinsSymphogen A/SCompletedMalignant GliomaUnited States
-
Jennifer KeiserPATH; Public Health Laboratory Ivo de CarneriCompleted
-
DBL -Institute for Health Research and DevelopmentCompleted